Hepatitis C

Hepatitis C features

• 

  Full speed ahead to curing hepatitis C

  New drugs that directly target the hepatitis C virus usher in a new era of treatment, Liz Highleyman reports. ...

  From:  HIV treatment update

• 

  We’re getting there: towards a comprehensive hepatitis C cure

  Research on new cures for hepatitis C has made rapid progress, Gus Cairns reports....

  From:  HIV treatment update

• 

  Staying safe inside: HIV and hepatitis C health care in prison

  Policies on safer sex and needle exchange in UK prisons seem to have stalled. With a high and increasing prevalence of hepatitis C in our jails, and...

  From:  HIV treatment update

• 

  Staying free of hepatitis C

  It's still not clear exactly how HIV-positive gay men are contracting hepatitis C through sex. Until we know with certainty, Derek Thaczuk asks, how can we avoid co-infection?...

  From:  HIV treatment update

• 

  Combinations and conundrums: the challenges of hepatitis C treatment

  A multiplicity of new drugs for hepatitis C are being researched. As Gus Cairns discovers, though, they face an elusive enemy, a shape-shifter of a virus that won’t...

  From:  HIV treatment update

• 

  The new epidemic: HIV and hepatitis C infection in gay men

  “I’m surprised there isn’t a greater sense of urgency about this in the community.” Those were the words of Dr Kevin Fenton of the US Centers for...

  From:  HIV treatment update

• 

  Double trouble – how hepatitis C is on the increase in HIV-positive gay men

  Studies at CROI showed how hepatitis C is gaining ground, says Gus Cairns. ...

  From:  HIV treatment update

• 

  Management of HIV and hepatitis B or C co-infection in resource-limited settings

  Review of management of HIV and hepatitis co-infection with particular focus on antiretroviral therapy and liver disease in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  Viral hepatitis in low and middle-income settings

  Management of HIV and hepatitis B or C co-infection in resource-limited settings....

  From:  HIV & AIDS treatment in practice

Hepatitis C in your own words

• 

  Living with HIV and hep C co-infection and haemophilia

  For most people, coping with HIV is enough of a problem in itself, but when you throw in a lifetime disorder such as haemophilia, and...

  From: In your own words

Hepatitis C news from aidsmap

• 'War on drugs' fuelling the hepatitis C epidemic among people who inject drugs

  The global war on drugs has had a disastrous impact on the hepatitis C epidemic, a new report from the Global Commission on Drug Policy shows. The Negative Impact of the War on Drugs on Public Health: The Hidden ...

  29 May 2013 | Michael Carter

• Triple therapy for hepatitis C is effective after liver transplantation, but side-effects are common

  Adding the approved HCV protease inhibitor telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin can increase sustained viral response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at the 48th International Liver Congress ...

  16 May 2013 | Liz Highleyman

• New HCV combinations could have a big role in prevention, but only if treatment rates increase

  New combinations of hepatitis C drugs could have major public health benefits, a modelling study published in the online edition of Hepatology shows. Scaling-up treatment rates in Edinburgh, Melbourne and Vancouver has the potential to achieve significant reductions in prevalence ...

  11 May 2013 | Michael Carter

• Report highlights major failings in UK response to hepatitis C

  The UK needs to “be doing so much more” in response to hepatitis C, according to a new report. Supported by a consortium of leading hepatitis C charities, Confronting the silent epidemic: a critical review of hepatitis C management ...

  07 May 2013 | Michael Carter

• Daclatasvir + asunaprevir + BMS-791352 looks promising as interferon-free combination

  An all-oral regimen containing three next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1 chronic hepatitis C patients in a phase 2a study, according to interim ...

  02 May 2013 | Liz Highleyman

• Compassionate access to new hepatitis C drugs an "emergency" for European patients

  European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at the 48th International Liver Congress (EASL 2013) ...

  30 April 2013 | Keith Alcorn

• Liver disease a major cause of illness and death across the EU: action needed to save lives

  Liver disease is the cause of a considerable burden of illness across the European Union (EU), investigators report in The Journal of Hepatology. The authors calculate that 170,000 deaths each year are attributable to liver cirrhosis, with 47,000 of these ...

  16 April 2013 | Michael Carter

• Hepatitis C epidemic in US gay men is decades old

  Hepatitis C virus (HCV) transmissions have been occurring in gay men since at least the early years of the HIV epidemic, investigators from the US report in the online edition of Clinical Infectious Diseases. The vast majority of ...

  10 April 2013 | Michael Carter

• Drinking coffee halves the risk of liver cancer

  Coffee consumption reduces the risk of liver cancer by approximately 50%, the results of a meta-analysis published in the online journal BMC Gastroenterology show. A total of 16 studies published before May 2012 were included in the analysis. Closer examination ...

  02 April 2013 | Michael Carter

• Sexual transmission of hepatitis C very rare in monogamous heterosexual couples

  Sexual transmission of hepatitis C virus (HCV) among monogamous heterosexual couples is extremely rare, investigators from the United States report in Hepatology. The maximum incidence of sexual transmission was just 0.07% per year, equivalent to just one transmission per 190,000 ...

  26 March 2013 | Michael Carter

More news

Hepatitis C news selected from other sources

• Blood tests OK for fibrosis diagnosis in hep C

  Blood testing can accurately identify clinically significant fibrosis and cirrhosis in people with hepatitis C virus (HCV) infection and may be an alternative to liver biopsy in some patients, a new systematic review has found.

  05 June 2013 | MedPage Today

• Drugs Go From Hit to Dud in Two Years in Hepatitis Race

  The pace of innovation, spurred by drugmakers jostling for a slice of a market that may reach $15 billion by 2018, has turned hepatitis C research into one of the fastest-developing areas of medicine. That boosted Gilead’s shares to a record last month, and left others like Vertex facing dwindling sales as their products quickly go from revolutionary to outdated.

  04 June 2013 | Bloomberg

• INCIVO® (telaprevir) Receives European Commission Approval for Twice Daily Dosing for Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV)

  Janssen Infectious Diseases-Diagnostics announced today that the European Commission has approved a new twice-daily dosing of INCIVO® (telaprevir), a direct-acting antiviral hepatitis C protease inhibitor, in combination with pegylated-interferon and ribavirin (PR) for naive and previous-treatment experienced patients.

  31 May 2013 | PR Newswire

• An all-oral combination phase II study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C virus infection initiated

  Medivir today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1, evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of simeprevir, a once-daily protease inhibitor jointly developed by Medivir and Janssen R&D Ireland, and samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor.

  30 May 2013 | Medivir

• Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets

  A new analysis from Frost & Sullivan, "Analysis of European Hepatitis B and C Therapeutics Markets" finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period.

  01 May 2013 | PR Newswire

• Statins tied to lowered liver cancer risk with hepatitis C

  People infected with chronic hepatitis C are less likely to develop liver cancer if they are taking cholesterol-lowering drugs, new research from Taiwan suggests.

  22 March 2013 | Reuters

• The New Deal: Gay Men, Sex, and Hep C

  A new website has been launched, in order to provide gay men with information about sexual transmission of hepatitis C and how to prevent it; testing for and treatment of hepatitis C; and information about HIV and hepatitis C co-infection.

  21 March 2013 | AFAO

• Conference Highlights: EASL Monothematic Conference: HIV and the Liver

  This was the first conference of its kind bringing together hepatologists and infectious disease specialists to address one of the critical issues in the management of HIV-infected patients: the rising mortality from liver disease. The Conference Highlights report features the key topics discussed and presented during the EASL Monothematic Conference. Email to a friend // // EASL would like to thank everyone who attended the EASL Monothematic Conference HIV and the Liver in London, UK, at the beginning of December 2012 and also thanks the European AIDS Clinical Society (EACS) for co-sponsoring the [...]

  14 March 2013 | European Association for the Study of the Liver (EASL)

• Expanding High Risk Population Drives European Hepatitis B and C Diagnostics Market

  New analysis from Frost & Sullivan, Analysis of the European Hepatitis B and C Diagnostics Market, estimates revenues of the hepatitis B diagnostics to grow from $165.9 million in 2012 to $260.2 million in 2019 and hepatitis C diagnostics market to grow from $3,140.8 million in 2012 to $4,940.9 million in 2019, respectively.

  13 March 2013 | PR Newswire (press release)

• England: lack of planning for hepatitis C services risks future chaos and huge healthcare costs

  New report finds that local authorities and NHS organisations need to prioritise hepatitis C now or risk missing a rare opportunity.

  11 March 2013 | Hepatitis C Trust press release

More news